Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 55 min ago
Peer-reviewedCC BY-NC 4.0Clinical Epidemiology

Hematologic Malignancies Survival Patterns in Elderly Patients: Disparities in Martinique, a Caribbean Population-Based Registry Study, 2008-2021

  • Adrian Puello1,2
  • Mylene Vestris1
  • Jonathan Macni1
  • Murielle Beaubrun-Renard1
  • Martial Boisseau3
  • Pascal Fuseau4
  • Lauren Peres5
  • Moustapha Dramé2,6
  • Clarisse Joachim1,2
6 affiliations
  1. 1Registre General Des Cancers de la Martinique, Pôle de Cancérologie-Hématologie-Urologie, Centre Hospitalier Universitaire de Martinique (CHU), Fort-de-France, Martinique, France
  2. 2EpiCliV Research Department, Faculty of Medicine, University of the Antilles, Fort-de-France, Martinique, France
  3. 3Hematology Department, Pôle de Cancérologie-Hématologie-Urologie, Centre Hospitalier Universitaire de Martinique (CHU), Fort-de-France, Martinique, France
  4. 4Biology-Hematology Department, Pôle Biologie-Pathologies, Centre Hospitalier Universitaire de Martinique (CHU), Fort-de-France, Martinique, France
  5. 5Cancer Epidemiology Department, Moffitt Cancer Center, Tampa, FL, USA
  6. 6Clinical Research and Innovation Department, Centre Hospitalier Universitaire de Martinique (CHU), Fort-de-France, Martinique, France
Read full textPDFDOICite

Abstract

Background: Disparities in Hematologic Malignancies (HM) including Leukemia, Non-Hodgkin Lymphoma, Myeloproliferative/Myelodysplastic Syndromes, and Myeloma, management based on geographic location and ethnicity remain a pressing global challenge. In the French Caribbean, HM are poorly understood, and elderly patients face significant disparities in survival and treatment access. This study aimed to characterize survival patterns and prognostic factors in elderly patients with HM in Martinique using population-based registry data.

Methods: Overall survival was estimated by Kaplan-Meier methods (95% CI) in 1,309 patients with HM aged ≥65 years, stratified by age, sex, histology, and chemotherapy. A Cox proportional hazards regression model was constructed to assess survival disparities incorporating age, sex, HM category, and geographic residency as covariates.

Results: Across 2008–2021 the median survival of patients with HM was 2.86 years. Marked variability was observed across diagnostic periods: median survival was 2.58 years in 2008–2012, 3.48 years in 2013–2017, and 2.76 years in 2018–2021. Myeloproliferative/Myelodysplastic Syndromes and Non-Hodgkin Lymphoma showed age-specific survival declines in the 75–84 age group during 2018–2021. For Myeloma, five-year survival improved from 49% (2008–2012) to 58% (2018–2021) in the 65–74 age group, while declining from 48% to 34% in the 75–84 age group. In Leukemia, five-year survival in the 75–84 age group increased from 7% (2008–2012) to 22% (2018–2021), while no clear change was observed in the 65–74 age group and estimates for the ≥85 age group were not calculable in all periods due to small case numbers.

Conclusion: This study offers novel insights into survival patterns of elderly patients with HM in the French Caribbean. Survival outcomes remain inferior to those reported in mainland France and high-income countries, possibly consistent with compounded healthcare interruptions and socioeconomic barriers. These findings underscore the urgent need for region-specific strategies, equitable care, and future research addressing the socioeconomic and genomic factors driving these disparities.

Related

  1. 454 Second primary hematologic malignancies in melanoma survivors before and after the introduction of immune checkpoint inhibitors: a population-based SEER analysis
    Jeffrey Afrifa-Yamoah, Damilola Ologbe, Duresha Malik +5
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  2. Seasonality of influenza virus, respiratory syncytial virus, rhinovirus and metapneumovirus in patients managed at a tertiary care hospital in Martinique (French Caribbean Island), 2016-2021.
    Moustapha Agossou, Sloane Rollier, Antoine Enfissi +7
    BMC infectious diseasesPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMCPMC
  3. Risk Factors and Outcomes of Vancomycin-Resistant Enterococcus faecium Bloodstream Infection in Hematologic Malignancies and Stem Cell Transplant Recipients: A Case-Control Study
    Open forum infectious diseasesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Non‐Relapse Mortality With Bispecific Antibodies in Hematologic Malignancies: A Dual Systematic Review and Pharmacovigilance Analysis
    Sohaib Irfan, Harshit Khosla, Saad Nasir +5
    Hematological oncologyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Global Burden of Disease Study on the Changing Landscape of Hematologic Malignancies and the Growing Impact of Elevated Body Mass Index — Asia, 1990–2023
    Yuan Wang, Ning Xu, Jingjing Guo +6
    China CDC weeklyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{puello2026hematologic,
  title = {{Hematologic Malignancies Survival Patterns in Elderly Patients: Disparities in Martinique, a Caribbean Population-Based Registry Study, 2008-2021}},
  author = {Adrian Puello and Mylene Vestris and Jonathan Macni and Murielle Beaubrun-Renard and Martial Boisseau and Pascal Fuseau and Lauren Peres and Moustapha Dramé and Clarisse Joachim},
  journal = {Clinical Epidemiology},
  year = {2026},
  month = oct,
  doi = {10.2147/clep.s629807},
  url = {https://doi.org/10.2147/clep.s629807},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Hematologic Malignancies Survival Patterns in Elderly Patients: Disparities in Martinique, a Caribbean Population-Based Registry Study, 2008-2021
AU  - Adrian Puello
AU  - Mylene Vestris
AU  - Jonathan Macni
AU  - Murielle Beaubrun-Renard
AU  - Martial Boisseau
AU  - Pascal Fuseau
AU  - Lauren Peres
AU  - Moustapha Dramé
AU  - Clarisse Joachim
PY  - 2026
DA  - 2026/10/30
JO  - Clinical Epidemiology
DO  - 10.2147/clep.s629807
UR  - https://doi.org/10.2147/clep.s629807
AB  - Background: Disparities in Hematologic Malignancies (HM) including Leukemia, Non-Hodgkin Lymphoma, Myeloproliferative/Myelodysplastic Syndromes, and Myeloma, management based on geographic location and ethnicity remain a pressing global challenge. In the French Caribbean, HM are poorly understood, and elderly patients face significant disparities in survival and treatment access. This study aimed to characterize survival patterns and prognostic factors in elderly patients with HM in Martinique using population-based registry data.  Methods: Overall survival was estimated by Kaplan-Meier methods (95% CI) in 1,309 patients with HM aged ≥65 years, stratified by age, sex, histology, and chemotherapy. A Cox proportional hazards regression model was constructed to assess survival disparities incorporating age, sex, HM category, and geographic residency as covariates.  Results: Across 2008–2021 the median survival of patients with HM was 2.86 years. Marked variability was observed across diagnostic periods: median survival was 2.58 years in 2008–2012, 3.48 years in 2013–2017, and 2.76 years in 2018–2021. Myeloproliferative/Myelodysplastic Syndromes and Non-Hodgkin Lymphoma showed age-specific survival declines in the 75–84 age group during 2018–2021. For Myeloma, five-year survival improved from 49% (2008–2012) to 58% (2018–2021) in the 65–74 age group, while declining from 48% to 34% in the 75–84 age group. In Leukemia, five-year survival in the 75–84 age group increased from 7% (2008–2012) to 22% (2018–2021), while no clear change was observed in the 65–74 age group and estimates for the ≥85 age group were not calculable in all periods due to small case numbers.  Conclusion: This study offers novel insights into survival patterns of elderly patients with HM in the French Caribbean. Survival outcomes remain inferior to those reported in mainland France and high-income countries, possibly consistent with compounded healthcare interruptions and socioeconomic barriers. These findings underscore the urgent need for region-specific strategies, equitable care, and future research addressing the socioeconomic and genomic factors driving these disparities.
SN  - 1179-1349
ER  -